News

Intensity Therapeutics Treats First Patient with Combination of INT230-6 and Merck’s Keytruda®

Intensity Therapeutics’ Intratumoral INT230-6 Tumor Regression and Immune Response Activity Data Selected for Oral Presentation at SITC 2019 Conference

Intensity Therapeutics’ CEO, Lewis H. Bender, Named One of PharmaVOICE’s 100 Most Inspiring People for 2019

Intensity Therapeutics’ INT230-6 Induces Immune Activation by Intratumoral Delivery as Reported in the Peer-Reviewed Journal OncoImmunology

Intensity Therapeutics Announces Clinical Collaboration with Merck

Intensity Therapeutics Presents Positive Preliminary Phase 1/2 Results for Intratumoral Injection of INT230-6 at ASCO 2019

Intensity Therapeutics to Present Data on Safety, Tumor Regression and Immune Activation of INT230-6 at ASCO 2019

Intensity Therapeutics to Present Data on Intratumoral Injection of INT230-6 at the Frontiers in Cancer Immunotherapy Symposium

Intensity Therapeutics Receives Fast Track Designation from U.S. FDA for Development of INT230-6 as Treatment for Relapsed or Metastatic Triple Negative Breast Cancer

Intensity Therapeutics Recognizes Rare Disease Day 2019

Intensity Therapeutics to Participate in Panel at 2019 BIO CEO & Investor Conference

Intensity Therapeutics Strengthens Intellectual Property Portfolio with Issuance of Several New Patents in Asia and Australia

Intensity Therapeutics Highlights INT230-6 Data in Advanced Solid Tumors at Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

Intensity Therapeutics Raises $6.5 Million in Series B Financing

Intensity Therapeutics Announces Preliminary Data from Clinical Study of INT230-6 in Advanced Solid Tumors

Intensity Therapeutics to Present Preliminary Data from Clinical Study of INT230-6 at Upcoming Medical Conferences

Intensity Therapeutics, Inc. Announces Presentation on INT230-6 Clinical Study at the 2018 ASCO conference.

Mark A. Goldberg, MD, Joins Intensity Therapeutics, Inc. Board of Directors

Intensity Therapeutics, Inc. Reports Positive Safety Data from On-going IT-01 Phase 1/2 Trial

Intensity Therapeutics Invited to Speak and Present at Upcoming Conferences